Xalud Therapeutics, Inc
Xalud Therapeutics, Inc., based in Berkeley, CA, is a clinical-stage biotechnology company pioneering a non-viral plasmid DNA (pDNA) gene therapy platform aimed at addressing chronic inflammation by restoring immune system balance. Their lead candidate, XT-150, leverages a proprietary version of interleukin-10 (IL-10v) to target various conditions, including musculoskeletal and neurodegenerative diseases, with a focus on treating the root causes of inflammation rather than merely alleviating symptoms.
The company's innovative approach promises adaptability and safety in delivering transgenes for a range of chronic inflammatory, neurological, and autoimmune disorders. Xalud is currently conducting clinical trials for XT-150, including a completed Phase 2b trial for osteoarthritis of the knee, while exploring diverse therapeutic applications through preclinical studies.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.